NanoViricides, Inc. (NNVC)
$1.26
Rating:
Recommendation:
Buy
| Symbol | NNVC |
|---|---|
| Price | $1.26 |
| Beta | 1.157 |
| Volume Avg. | 0.10M |
| Market Cap | 14.699M |
| Shares () | - |
| 52 Week Range | 1.04-2.0 |
| 1y Target Est | - |
| DCF Unlevered | NNVC DCF -> | |
|---|---|---|
| DCF Levered | NNVC LDCF -> | |
| ROE | -31.60% | Strong Sell |
| ROA | -35.19% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | - | |
| P/E | -2.03 | Sell |
| P/B | 0.80 | Buy |
Latest NNVC news
About
Download (Excel)NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.